Stage III Pancreatic Cancer Clinical Trial
Official title:
Electronic Monitoring of Patient-Reported Outcomes and Function in GI Cancer Surgery: A Feasibility Study
Verified date | January 2021 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot clinical trial studies an electronic monitoring device of patient-reported outcomes (PROs) and function in improving patient-centered care in patients with gastrointestinal cancer undergoing surgery. Electronic monitoring is a technology-based way of asking patients about the quality of life, symptoms, and activity using online surveys and an activity tracking watch may make it easier for patients to tell their doctors and nurses about any issues before and after surgery. Electronic systems of assessing PROs may increase the depth and accuracy of available clinical data, save administrative time, prompt early intervention that improves the patient experience, foster patient-provider communication, improve patient safety, and enhance the consistency of data collection across multiple sites.
Status | Completed |
Enrollment | 22 |
Est. completion date | July 31, 2016 |
Est. primary completion date | July 31, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Scheduled to undergo surgery for primary or secondary gastric, colorectal, liver, or pancreas cancer - Able to read and understand English - Patients across all stages of disease - There are no restrictions related to performance status or life expectancy - This protocol is eligible for waiver of informed consent documentation; all subjects must have the ability to understand and the willingness to provide verbal informed consent Exclusion Criteria: - Research participants who have no computer and internet access and/or do not use a computer even if one is present in the household - Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean time patients are able to tolerate wearing the wristband device, both before and after surgery | Descriptive statistics will be used to describe the distribution of time (before and after surgery) a patient is able to wear the wristband device. | Up to 1 month | |
Primary | Mean time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure | Descriptive statistics will be used to describe the distribution of time to complete each assessment. | Up to 1 month | |
Primary | Median time patients are able to tolerate wearing the wristband device, both before and after surgery | Descriptive statistics will be used to describe the distribution of time (before and after surgery) a patient is able to wear the wristband device. | Up to 1 month | |
Primary | Median time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure | Descriptive statistics will be used to describe the distribution of time to complete each assessment. | Up to 1 month | |
Primary | Percentage of patients who are able to complete the web-based questionnaires MDASI and EQ-5D | Descriptive statistics will be reported. Patients who complete at least 80% of all scheduled MDASI and EQ-5D questionnaires will be indicated as able to complete the web-based questionnaires. The true population proportion will be estimated with 95% confidence interval of half-width no more than 0.16. | Up to 1 month | |
Primary | Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively | Estimated with 95% confidence interval of half-width no more than 16%. | Up to 1 week post-operatively | |
Secondary | Ease of use of web-based surveys and wristband device, as measured by responses from Satisfaction Tool | Up to 1 month | ||
Secondary | Feedback on items in the web-based surveys that are distressing or difficult to comprehend, as measured by responses from Satisfaction Tool | Up to 1 month | ||
Secondary | Feedback on length of surveys and timing of administration, as measured by responses from Satisfaction Tool | Up to 1 month | ||
Secondary | Mean number of missing items within each questionnaire | Mean number of missing items within each questionnaire will be calculated to identify individual or subsets of questions that are difficult to answer. | Up to 1 month | |
Secondary | Percentage of patients who did not enroll in the study-composite outcome of multiple measure listed | Percentage of patients who did not enroll in the study will be determined and the reasons why will be analyzed. This will be accomplished using: i) the number of patients asked to participate, ii) the number of patients who declined to participate, and iii) reasons for declining participation. | Up to 1 month | |
Secondary | Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool | Up to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00020345 -
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT01068327 -
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00026104 -
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03899649 -
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
|
||
Terminated |
NCT01739439 -
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
|
Phase 1 | |
Completed |
NCT01821612 -
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
|
Early Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00323583 -
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A |